ArticleNeurology. Clinical practice2022
Orthostatic Hypotension in Parkinson Disease: What Is New?
Article in Neurology. Clinical practice, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 21 citations in OpenAlex.
- Refining Maximal Heart Rate Estimation to Enhance Exercise Recommendations for Persons With Parkinson Disease.Archives of physical medicine and rehabilitation · 2025Trial
- Effect of levodopa on postural blood pressure changes in Parkinson disease: a randomized crossover study.Clinical autonomic research : official journal of the Clinical Autonomic Research Society · 2024Trial
- Revealing Non-Motor Symptom Profiles of Orthostatic Hypotension Subtypes in Parkinson's Disease: Insights From a Multidimensional Case-Control Study.Clinical and translational science · 2026Article
- High intensity interval training for Parkinson's disease: A scoping review of systemic effects and physiological adaptations.Journal of Parkinson's disease · 2026Article
- Orthostatic hypotension in Parkinson's disease-More than just lightheadedness and fainting.Clinical autonomic research : official journal of the Clinical Autonomic Research Society · 2025Article
- Advice to people with Parkinson's in my clinic: Get a cardiopulmonary exercise test.Journal of Parkinson's disease · 2025Article
- Redefining Non-Motor Symptoms in Parkinson's Disease.Journal of personalized medicine · 2025Review
- Neurogenic Orthostatic Hypotension in Parkinson Disease-A Narrative Review of Diagnosis and Management.Journal of clinical medicine · 2025Review
- Approaches for treating cardiovascular symptoms in Parkinson's disease.Therapeutic advances in neurological disorders · 2025Review
- Orthostatic hypotension in Parkinson's disease: therapeutic considerations.Therapeutic advances in neurological disorders · 2025Review
- Levodopa-induced orthostatic hypotension in parkinsonism: A red flag of autonomic failure.European journal of neurology · 2024Article
- Chronotropic Incompetence During Exercise Testing as a Marker of Autonomic Dysfunction in Individuals with Early Parkinson's Disease.Journal of Parkinson's disease · 2024Article
- Advice to People with Parkinson's in My Clinic: Orthostatic Hypotension.Journal of Parkinson's disease · 2024Article
- Association of neurogenic orthostatic hypotension with cognitive decline in Parkinson's disease: a longitudinal cohort study.Frontiers in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose of the Review: Orthostatic hypotension (OH) is the primary manifestation of cardiovascular autonomic dysfunction in Parkinson disease (PD) and can be a prodromal feature of the disease. We review the recent progress in the field of autonomic dysfunction in PD. Recent Findings: Individuals with isolated neurogenic OH should be followed up frequently because they may evolve into PD, dementia with Lewy bodies, or multiple system atrophy. The prevalence of OH in PD increases with disease stages, but the role of levodopa remains unclear. Measurement of supine and standing heart rate and blood pressure allows for accurate identification of neurogenic OH in the clinic. Summary: Accurate identification of neurogenic OH in the clinic is crucial for identification of individuals who may benefit from participation in neuroprotective trials in the future. The treatment of OH in PD should be individualized and may reduce the risk of falls, cognitive impairment, and death.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.